Deucravacitinib Hits Primary Endpoints in Two Phase 3 PsA Studies
Deucravacitinib (Sotyktu, Bristol Myers Squibb) performed well in two Phase 3 studies of adults with active psoriatic arthritis (PsA). Both trials met their primary endpoint, with a significantly greater proportion of deucravacitinib -treated patients achieving ACR20 response (at least a 20% improvement in signs and symptoms of disease) after 16 weeks of treatment compared with […]